Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

ACADIA reports phase II topline results on pimavanserin for negative symptoms of schizophrenia

Nov. 26, 2019

UCB discovers synaptic vesicle glycoprotein 2A/2C ligands

Nov. 26, 2019

Soliris approved in Japan for neuromyelitis optica spectrum disorder

Nov. 25, 2019

New phase III trial evaluates oral formulation of edaravone for ALS

Nov. 25, 2019

New RIP-1 inhibitors identified at Rigel Pharmaceuticals

Nov. 25, 2019

Phase I data presented for TPI-287 in Alzheimer's disease and 4-repeat tauopathies

Nov. 25, 2019

Xcopri wins FDA approval for partial-onset seizures in adults

Nov. 22, 2019

New cannabinoid receptor modulators revealed in recent patent

Nov. 22, 2019

FDA approves phase I/II trial of Hope's adipose-derived mesenchymal stem cells for Alzheimer's

Nov. 21, 2019

Rigel Pharmaceuticals synthesizes RIPK1 inhibitors

Nov. 21, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...